Hormonal
GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) significantly reduce body weight and improve glycemic control in patients with type 2 diabetes and obesity by stimulating insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite.
For individuals with obesity or type 2 diabetes, GLP-1 and GLP-1/GIP receptor agonists are highly effective treatments that promote significant weight loss and improve blood sugar control. These medications work by mimicking natural hormones to increase insulin, reduce glucagon, slow digestion, and decrease appetite. While they can cause gastrointestinal side effects like nausea, starting with a low dose and increasing it slowly helps manage these symptoms. They are particularly beneficial for those who have not achieved sufficient weight loss or cardiovascular risk reduction with lifestyle changes alone.
GLP-1RAs exert their effects by stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite through the activation of the GLP-1 receptor. These agents have demonstrated significant efficacy in the management of type 2 diabetes mellitus (T2DM) and obesity.
Why this rating
The claim is supported by a comprehensive review of multiple randomized controlled trials, network meta-analyses, and large-scale cardiovascular outcome trials.
Source
The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review
Zhao Liu et al. · Drug Design Development and Therapy · 2025
DOI 10.2147/dddt.s559919
More from this paper
- GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.Strong
- GLP-1RAs exhibit neuroprotective effects and may improve symptoms in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and cognitive dysfunction associated with type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →